RIMSO-50 500 MG / G
RIMSO-50 · DIN 00493392 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is RIMSO-50?
RIMSO-50 500 MG / G contains RIMSO-50. It is listed in the Health Canada Drug Product Database under DIN 00493392, held by MYLAN PHARMACEUTICALS ULC. Health Canada currently lists it as marketed, status dated 31-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIMSO-50 used for?
Symptomatic relief of patients with interstitial cystitis. Not approved for any other indication or bacterial infections of the urinary tract.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00493392 |
|---|---|
| Brand name | RIMSO-50 |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 500 MG / G |
| Schedule | PRESCRIPTION |
| Health Canada status | MARKETED |
| Status date | 31-Oct-2018 |
How is it administered?
Instill 50 mL directly into the bladder via catheter or syringe; retain for 15 minutes then void. Repeat every two weeks until relief is obtained. May be diluted 1:1 with sterile water if needed.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15° and 30°C and protected from light.
How is it supplied?
Bottles containing 50 mL (54 gm).
Contraindications
None.
Warnings and precautions
Can initiate histamine liberation; potential for hypersensitivity/anaphylactoid reactions. May be harmful in patients with urinary tract malignancy due to vasodilation. Full eye exams recommended.
Is RIMSO-50 in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by MYLAN PHARMACEUTICALS ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.